Amalus Therapeutics develops innovative approach for treating patients with cancer or fibrotic diseases

Ghent University and the booming Ghent biotech landscape welcome a brand new spin-off: Amalus Therapeutics is developing a new class of drugs that selectively target corrupt fibroblast cells.

Related Keywords

United Kingdom ,Belgium ,Copenhagen ,Køavn ,Denmark ,Danish ,Belgian ,Bart Roman ,Christian Stevens ,Oxford Business Network ,Novo Nordisk Foundation ,Ghent University ,Bioinnovation Institute Venture Lab ,Ghent University Cancer Research Institute ,Bioinnovation Institute Foundation ,Amalus Therapeutics ,Bioinnovation Institute ,Venture Lab ,Cancer Research Institute Ghent ,Bio Organic Chemistry ,One To Watch Award ,Cancer ,Ibrosis ,Drugs ,Fibroblast ,Immune System ,Herapeutics ,Humor ,